85
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Nine-Year Follow-Up of Interleukin 6 in Chronic Obstructive Pulmonary Disease – Complementary Results from Previous Studies

ORCID Icon, ORCID Icon, ORCID Icon, , , & ORCID Icon show all
Pages 3019-3026 | Published online: 03 Nov 2021

References

  • Prudente RA, Tanni SE. Interleucina 6 de pacientes com DPOC em nove anos; 2020.
  • Prudente R, Mesquita C, Franco E, Ferrari R, Godoy I, Tanni S. Role of interleukin 6 in COPD patients over nine years. Eur Respir J. 2020;56:2471. doi:10.1183/13993003.congress-2020.2471.
  • Singh D, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5):1900164. doi:10.1183/13993003.00164-2019
  • Wouters EFM. Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(1):26–33. doi:10.1513/pats.200408-039MS
  • Dourado VZ, Tanni SE, Vale SA, Faganello MM, Sanchez FF, Godoy I. Manifestações sistêmicas na doença pulmonar obstrutiva crônica. J Bras Pneumol. 2006;32(2):161–171. doi:10.1590/S1806-37132006000200012
  • Rabe KF, Beghé B, Luppi F, Fabbri LM. Update in chronic obstructive pulmonary disease 2006. Am J Respir Crit Care Med. 2007;175(12):1222–1232. doi:10.1164/rccm.200704-586UP
  • Ahmadi-Abhari S, Kaptoge S, Luben RN, Wareham NJ, Khaw KT. Longitudinal association of C-reactive protein and lung function over 13 years: the EPIC-Norfolk Study. Am J Epidemiol. 2014;179(1):48–56. doi:10.1093/aje/kwt208
  • MacNee W. Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2:50–60. doi:10.1513/pats.200411-056SF.
  • Agustí A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012;7(5):e37483. doi:10.1371/journal.pone.0037483
  • Ferrari R, Tanni SE, Caram LMO, Corrêa C, Corrêa CR, Godoy I. Three-year follow-up of Interleukin 6 and C-reactive protein in chronic obstructive pulmonary disease. Respir Res. 2013;14(1):24. doi:10.1186/1465-9921-14-24
  • Smith BM, Jensen D, Brosseau M, Benedetti A, Coxson HO, Bourbeau J. Impact of pulmonary emphysema on exercise capacity and its physiological determinants in chronic obstructive pulmonary disease. Sci Rep. 2018;8(1). doi:10.1038/s41598-018-34014-5
  • Garudadri S, Woodruff PG, Han MLK, et al. Systemic markers of inflammation in smokers with symptoms despite preserved spirometry in SPIROMICS. Chest. 2019;155(5):908–917. doi:10.1016/j.chest.2018.12.022
  • Souza JRM, Oliveira RT, Blotta MHSL, Coelho OR. Níveis séricos de interleucina-6 (IL-6), interleucina-18 (IL-18) e proteína C reativa (PCR) na síndrome coronariana aguda sem supradesnivelamento do ST em pacientes com diabete tipo 2. Arq Bras Cardiol. 2008;90(2):94–99. doi:10.1590/S0066-782X2008000200004
  • Shapiro SD. Evolving concepts in the pathogenesis of chronic obstructive pulmonary disease. Clin Chest Med. 2000;21(4):621–632. doi:10.1016/S0272-5231(05)70172-6
  • Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003;22(4):672–688. doi:10.1183/09031936.03.00040703
  • Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138. doi:10.1056/nejmoa0909883
  • Menezes AMB, Jardim JR, Pérez-Padilla R, et al. Prevalence of chronic obstructive pulmonary disease and associated factors: the PLATINO Study in São Paulo, Brazil. Cad Saude Publica. 2005;21(5). doi:10.1590/S0102-311X2005000500030
  • Faganello MM, Tanni SE, Sanchez FF, Pelegrino NRG, Lucheta PA, Godoy I. BODE index and GOLD staging as predictors of 1-year exacerbation risk in chronic obstructive pulmonary disease. Am J Med Sci. 2010;339(1):10–14. doi:10.1097/MAJ.0b013e3181bb8111
  • Ferrari R, Tanni SE, Faganello MM, Caram LMO, Lucheta PA, Godoy I. Three-year follow-up study of respiratory and systemic manifestations of chronic obstructive pulmonary disease. Braz J Med Biol Res. 2011;44(1):46–52. doi:10.1590/S0100-879X2010007500150
  • Moreira GL, Manzano BM, Gazzotti MR, et al. PLATINO, estudo de seguimento de nove anos sobre DPOC na cidade de São Paulo: o problema do subdiagnóstico. J Bras Pneumol. 2014;40(1):30–37. doi:10.1590/S1806-37132014000100005
  • Tanni SE, Zamuner ATS, Coelho LS, Vale SA, Godoy I, Paiva SAR. Are metabolic syndrome and its components associated with 5-year mortality in chronic obstructive pulmonary disease patients? Metab Syndr Relat Disord. 2015;13(1):52–54. doi:10.1089/met.2014.0100
  • Prudente R, Franco EAT, Mesquita CB, Ferrari R, De godoy I, Tanni SE. Predictors of mortality in patients with COPD after 9 years. Int J COPD. 2018;13:3389–3398. doi:10.2147/COPD.S174665
  • Marchioro J, Gazzotti MR, Moreira GL, et al. Anthropometric status of individuals with COPD in the city of São Paulo, Brazil, over time-analysis of a population-based study. J Bras Pneumol. 2019;45(6). doi:10.1590/1806-3713/e20170157
  • Prudente R, Ferrari R, Mesquita CB, et al. Peripheral blood eosinophils and nine years mortality in COPD patients. Int J COPD. 2021;16:979–985. doi:10.2147/COPD.S265275
  • Wei J, Xiong XF, Lin YH, Zheng BX, Cheng DY. Association between serum interleukin-6 concentrations and chronic obstructive pulmonary disease: a systematic review and meta-analysis. PeerJ. 2015;2015(8):e1199. doi:10.7717/peerj.1199
  • Garcia-Rio F, Miravitlles M, Soriano JB, et al. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res. 2010;11(1):1–5. doi:10.1186/1465-9921-11-63
  • Jakeways N, McKeever T, Lewis SA, Weiss ST, Britton J. Relationship between FEV1 reduction and respiratory symptoms in the general population. Eur Respir J. 2003;21(4):658–663. doi:10.1183/09031936.03.00069603
  • Tantucci C, Modina D. Lung function decline in COPD. Int J COPD. 2012;(7):95. doi:10.2147/COPD.S27480
  • Mehrotra N, Freire AX, Bauer DC, et al. Predictors of mortality in elderly subjects with obstructive airway disease: the PILE Score. Ann Epidemiol. 2010;20(3):223–232. doi:10.1016/j.annepidem.2009.11.005
  • Celli BR, Locantore N, Yates J, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185(10):1065–1072. doi:10.1164/rccm.201110-1792OC
  • Pinto-Plata V, Casanova C, Müllerova H, et al. Inflammatory and repair serum biomarker pattern. Association to clinical outcomes in COPD. Respir Res. 2012;13(1):71. doi:10.1186/1465-9921-13-71
  • Fermont JM, Masconi KL, Jensen MT, et al. Biomarkers and clinical outcomes in COPD: a systematic review and meta-analysis. Thorax. 2019;74(5):439–446. doi:10.1136/thoraxjnl-2018-211855
  • Nunes LN, Klück MM, Fachel JMG. Multiple imputations for missing data: a simulation with epidemiological data. Cad Saude Publica. 2009;25(2):268–278. doi:10.1590/s0102-311x2009000200005
  • Khan NA, Daga MK, Ahmad I, et al. Evaluation of BODE index and its relationship with systemic inflammation mediated by proinflammatory biomarkers in patients with COPD. J Inflamm Res. 2016;9:187–198. doi:10.2147/JIR.S108783
  • Sørensen AK, Holmgaard DB, Mygind LH, Johansen J, Pedersen C. Neutrophil-to-lymphocyte ratio, calprotectin and YKL-40 in patients with chronic obstructive pulmonary disease: correlations and 5-year mortality - A cohort study. J Inflamm. 2015;12(1):1–2. doi:10.1186/s12950-015-0064-5
  • Acanfora D, Scicchitano P, Carone M, et al. Relative lymphocyte count as an indicator of 3-year mortality in elderly people with severe COPD. BMC Pulm Med. 2018;18(1):1–8. doi:10.1186/s12890-018-0685-6
  • Xiong W, Xu M, Zhao Y, Wu X, Pudasaini B, Liu JM. Can we predict the prognosis of COPD with a routine blood test? Int J COPD. 2017;12:615–625. doi:10.2147/COPD.S124041
  • Lee H, Um SJ, Kim YS, et al. Association of the neutrophil-to-lymphocyte ratio with lung function and exacerbations in patients with chronic obstructive pulmonary disease. PLoS One. 2016;11(6):e0156511. doi:10.1371/journal.pone.0156511